

Singapore to receive APAC's first-of-its-kind Digital Brain Health Screening

13 June 2022 | News

Patients in Singapore are the first in the APAC region to access rapid, fully digitised, cost-effective brain health cognitive assessments



Singapore's Parkway Shenton becomes the first primary healthcare provider in the Asia Pacific to provide digital brain screening and monitoring using Neurowyze's proprietary Digital Brain Function Scan. This can enable earlier recognition of brain health problems that are associated with cognitive decline, stroke, Long Covid brain damage, Parkinson's disease and dementia.

Neurowyze, the Singapore Brain Capital company which leverages neuroscience-based digital solutions, has announced a partnership with Parkway Shenton to facilitate digital brain health screening and monitoring tools.

Singaporeans can now have access to a digital neuroscience tool that enables the early detection of cognitive decline. Quick, affordable, and available through an online portal after being prescribed by a physician. Neurowyze's medical-grade Digital Brain Function Scan can be connected to a device (such as a mobile phone, iPad, laptop or PC) and a browser to complete an assessment within minutes. This reduces the need for multiple clinic visits and expenses to understand the health of the brain.

The World Health Organisation and leading clinical neuroscientists recommend brain cognitive screening for all adults as part of routine healthcare screening. Neuroscience studies show that from the age of 30, nearly 10 percent of people experience a brain health problem called Mild Cognitive Impairment (MCI).

People that are at higher risk of brain health problems such as MCI include those with undetected and untreated or poorly-controlled chronic Non-Communicable Diseases (NCD) such as hypertension, diabetes, obesity, metabolic syndrome, and high cholesterol, and high lipids.